Novartis AG (NVS)

NYSE - NYSE Real Time Price. Currency in USD
79.05-0.20 (-0.25%)
As of 11:54 AM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close79.25
Bid78.87 x 200
Ask78.88 x 300
Day's Range78.28 - 79.06
52wk Range69.90 - 95.11
1y Target EstN/A
Market Cap188.41B
P/E Ratio (ttm)28.22
Avg Vol (3m)1,299,531
Dividend & Yield2.72 (3.35%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • American City Business Journals5 hours ago

    SQZ Biotech nabs $16M funding, hires former Novartis exec

    A startup based at UMass Boston’s Venture Development Center that’s developed a unique way of getting molecules inside living cells has announced a $16 million investment and the hiring of a former Novartis executive as chief business officer. SQZ Biotech, headed by 29-year-old co-founder and CEO Armon Sharei, says the Series B investment was led by two venture firms, NanoDimension and Polaris Partners. Boston-based Polaris was behind a $5 million round the company received in June 2015 , and partner Amy Schulman (also executive chairwoman of SQZ) said that the company has made “remarkable progress” since it was founded in 2013.

  • Investopedia19 hours ago

    Amgen Maintains Migraine Drug Lead (AMGN)

    Amgen leads the migraine drug race by being the first company to publish phase 3 results, but intense competition looms in the future

  • Investor's Business Daily20 hours ago

    Amgen Migraine Drug Likely To Beat Eli Lilly, Alder, Teva To Market

    Amgen will likely beat Eli Lilly, Alder and Teva to market with an antibody-blocking migraine med.